What is the difference between vitamin K1 and K2?

Vitamin K1 (phylloquinone) is primarily involved in blood clotting and is found in green leafy vegetables like spinach and kale. Vitamin K2 (menaquinone) activates proteins that regulate calcium distribution, specifically osteocalcin for bone and MGP for arteries. K2 is found in fermented foods like natto, aged cheese, and animal products.

Why is MK-7 preferred over MK-4?

MK-7 has a much longer half-life, approximately 72 hours, which allows once-daily dosing to maintain stable blood levels. MK-4 has a half-life of 1 to 2 hours, requiring multiple daily doses at higher amounts to achieve comparable coverage. Clinical trials demonstrating arterial stiffness improvements have primarily used MK-7.

Should I take vitamin K2 with vitamin D?

Vitamin D increases calcium absorption from food. Vitamin K2 directs that absorbed calcium to bones rather than allowing it to accumulate in arteries. Taking D without K2 may increase circulating calcium without fully optimizing where it is deposited. Studies show that co-supplementation produces higher levels of activated MGP compared to vitamin D alone.

Vitamin K2 MK-7: The Dual Role of Sending Calcium to Bones and Out of Arteries

Anyone who has taken calcium supplements may have encountered a disconcerting question: can calcium end up in arteries instead of bones? The calcium paradox describes exactly this: bone mineral loss and arterial calcification occurring simultaneously in the same person. Vitamin K2, particularly in MK-7 form, addresses this through a specific molecular pathway that most calcium and vitamin D supplementation overlooks.

The Calcium Paradox Explained

Bone loss and arterial calcification are not separate problems. They share a common regulatory system, and vitamin K2 sits at the center of it.

When the K2-dependent system is functioning well, calcium absorbed from food is directed preferentially into bone tissue and kept out of arterial walls. When K2 is insufficient, two critical proteins remain in their inactive forms, and calcium distribution becomes dysregulated.

The first protein is osteocalcin. Produced by osteoblasts (the cells that build bone), osteocalcin binds calcium and incorporates it into the bone matrix. Without vitamin K2, osteocalcin cannot be carboxylated (activated), and its ability to anchor calcium into bone is severely reduced.

The second protein is MGP (Matrix Gla Protein), produced by vascular smooth muscle cells. When activated by K2, MGP inhibits calcium from depositing in arterial walls. Uncarboxylated MGP (ucMGP) is the inactive form, and elevated ucMGP in the blood is now used as a marker of K2 insufficiency and vascular calcification risk.

The 3-Year Clinical Trial

The most frequently cited study is a Dutch double-blind randomized controlled trial in healthy postmenopausal women. Participants received either 180 mcg of MK-7 daily or placebo for three years.

At the end of the trial, the MK-7 group showed significant improvements in arterial elasticity, measured by reduced carotid artery stiffness. Carboxylated (active) osteocalcin and MGP levels were meaningfully higher in the supplementation group, confirming that the proteins were being activated. These changes were not seen in the placebo group.

Meta-analyses of bone density studies consistently find that vitamin K2 supplementation slows the rate of bone loss, particularly in postmenopausal women, where estrogen decline accelerates osteoclast activity and bone resorption.

Why MK-7 Specifically

MK-7 is the long-chain form of vitamin K2, naturally present in natto (fermented soybeans). Its 72-hour half-life means blood levels remain stable with once-daily dosing. This is the pharmacological reason MK-7 is the form used in clinical trials and the form that research findings apply to.

MK-4, the short-chain form, is rapidly metabolized with a 1 to 2 hour half-life. While it has biological activity, maintaining steady blood levels requires frequent dosing at higher amounts. Clinical data for arterial and bone outcomes comes primarily from MK-7 studies.

The research-supported dose range for MK-7 is 100 to 200 mcg per day, with 180 mcg being the dose used in the three-year postmenopausal trial.

Combining K2 and Vitamin D

Vitamin D3 drives calcium absorption in the intestine. Vitamin K2 determines where that calcium goes afterward. Without K2, higher calcium absorption from vitamin D does not guarantee more calcium reaching bone.

Several studies have compared D3 alone versus D3 combined with K2. The combination consistently produces higher levels of activated MGP and improved carboxylation of osteocalcin. For those supplementing vitamin D at higher doses, K2 is the logical complement.

Important note: vitamin K directly interacts with anticoagulant medications including warfarin. Anyone taking blood thinners should consult a physician before adding K2 supplementation.

What This Means After Menopause

The postmenopausal decade is when both bone loss and cardiovascular risk escalate. Estrogen protects against bone resorption and supports vascular elasticity. As estrogen declines, both pathways become more vulnerable.

K2 MK-7 addresses both simultaneously through the same two-protein mechanism. This makes it particularly relevant for women navigating the years when bone density scans and cardiovascular screening both become part of routine care.

Source: PMC / Nutraceutical Business Review